CING - Cingulate Inc. News

Cingulate Joins Russell 3000E Index

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutio

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceuti

Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts OR

Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday

Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analys

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $52

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Pa

12 Health Care Stocks Moving In Wednesday's Intraday Session

reuters.com

US FDA declines to approve Cingulate's ADHD drug

Cingulate said on ‌Tuesday that the U.S. Food ⁠and Drug Administration declined to approve its

Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Info

The response identified specific Chemistry, Manufacturing and Controls (CMC) information requests an

Cingulate Receives Complete Response Letter from FDA for CTx-1301

No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on C

HC Wainwright & Co. Reiterates Buy on Cingulate, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cingulate (NASDAQ:CING) with a Buy

Cingulate Q1 EPS $(0.95) Misses $(0.53) Estimate

Cingulate (NASDAQ:CING) reported quarterly losses of $(0.95) per share which missed the analyst cons

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Rea

KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutic

12 Health Care Stocks Moving In Wednesday's After-Market Session

Amazon To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday

Wall Street analysts changed outlook on top names. See all changes on Benzinga's analyst ratings

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $55

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital P

Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $14

Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lower

What's Going On With Cingulate Stock Today?

Cingulate slipped in premarket trading as investors weighed its wider quarterly loss against a fresh

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

Cingulate Q4 EPS $(0.84) Misses $(0.61) Estimate

Cingulate (NASDAQ:CING) reported quarterly losses of $(0.84) per share which missed the analyst cons

invezz.com

Why did Cingulate stock skyrocket today?

Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPT

12 Health Care Stocks Moving In Thursday's Pre-Market Session

defenseworld.net

Cingulate Inc. (NASDAQ:CING) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have earned a consensus rating of "Moderat

defenseworld.net

Cingulate Inc. (NASDAQ:CING) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have been assigned an average rating of "M

Cingulate CEO Shane Schaffer Reinstated Following Legal Matter; Mr. Roberts To No Longer Serve As Ex

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $58

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the

Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $16

Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lower

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capit

Cingulate Releases Phase 3 Trial Results For Its ADHD Treatment CTX-1301 Showing The Drug Met Its Pr

Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of nex

Cingulate's Data From Lead ADHD Candidate CTx-1301 Selected For Podium Presentation At AACAP Annual

Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of nex

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential

Roth Capital Maintains Buy on Cingulate, Raises Price Target to $17

Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and raise

12 Health Care Stocks Moving In Tuesday's After-Market Session

Cingulate Announces That U.S. FDA Accepts For Review Its New Drug Application For CTx-1301, Its Lead

Cingulate Inc. (NASDAQ:CING) a biopharmaceutical company developing and advancing a pipeline of next

Cingulate Enters Commercial Supply Agreement With Bend Bio Sciences For Manufacturing Of CTx-1301, I

Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Comme

Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval

Ascendiant Capital Maintains Buy on Cingulate, Raises Price Target to $62

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Dallas, Texas--(Newsfile Corp. - August 21, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital

Cingulate Q2 EPS $(1.09) Misses $(0.84) Estimate

Cingulate (NASDAQ:CING) reported quarterly losses of $(1.09) per share which missed the analyst cons

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301 Anticipate FDA Decision in Q

Cingulate Appoints Jennifer Callahan As Interim CEO; Names Jay Roberts Executive Chairman

Jennifer Callahan, Chief Financial Officer, appointed Interim CEOBoard member, Jay Roberts appointed

Cingulate Provides Management Team Update

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointe

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Regulatory filing marks significant milestone for medication designed to provide once-daily, entire

12 Health Care Stocks Moving In Wednesday's After-Market Session

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Dallas, Texas--(Newsfile Corp. - June 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital P

https://www.prnewswire.com

Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

Industry Leader with 30+ Years of Experience Will Drive Strategic Growth and Partnerships SCOTTSDALE